Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hewlett Packard Enterprise Co (HPE) vs 10X Genomics Inc (TXG) Price & Performance

Hewlett Packard Enterprise CoTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Hewlett Packard Enterprise Co vs 10X Genomics Inc — how do they compare? Hewlett Packard Enterprise Co trades at $56.15 (market cap $72.01B), while 10X Genomics Inc trades at $58.55 (market cap $7.61B). The key difference: Hewlett Packard Enterprise Co is far larger — about 9.5× 10X Genomics Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

HPETXG
Market Cap
$72.01B$7.61B
Sector
TechnologyHealth
52-Week High
$56.14$58.57
52-Week Low
$20.01$11.34
Enterprise Value
$87.96B$7.14B
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hewlett Packard Enterprise Co

HPE stock trades at $54.67, up 2.72% recently, with a bullish technical signal from moving averages but overbought RSI readings. The company has beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.925. Revenue grew to $34.30B in 2025, though net income fell sharply to $57M due to high investing cash outflows. Analysts maintain a consensus buy rating with a $69.81 price target, citing AI infrastructure demand.

The outlook is positive given AI-driven upgrades and institutional buying, but risks include volatile cash flows, elevated debt, and margin pressure. Investors should weigh strong analyst sentiment against execution risks in a competitive market.

10X Genomics Inc

TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.

Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.

Read more on HPE

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG